Medications and Therapies for MDS
At a Glance
Treatment for myoclonus-dystonia syndrome is individualized and may combine medication trials with targeted botulinum toxin, mental health care, and rehabilitation. Zonisamide has the strongest evidence for movement-related jerks, but dosing and safety monitoring must be managed by a clinician.
Managing Myoclonus-Dystonia Syndrome (MDS) requires a “whole-person” approach. While there is currently no cure, there are strategies to reduce the physical jerks and manage the psychiatric challenges that often come with the condition [1][2]. Because MDS affects both movement and mental health, a multidisciplinary care team—usually led by a movement disorder neurologist and a psychiatrist or neuropsychologist—is essential for the best outcomes [2].
Medications for Motor Symptoms
Treatment for the physical movements in MDS is often empirical, meaning your doctor may need to try several medications to find the one that works best for your specific biology [3].
Zonisamide: The Leading Evidence
Among all oral medications, Zonisamide has the strongest scientific backing for MDS [1].
- What the research says: A high-quality (Class I) clinical trial showed that Zonisamide significantly improved both the severity of “action myoclonus” (jerks that happen during movement) and the disability it causes in daily life [1].
- Dosage and Titration: In studies, the dose was slowly increased (titrated) over six weeks to reach a target of 300 mg per day [1][4]. However, this reflects a specific study regimen and is generally off-label for MDS. Your dose must be individualized by your doctor—never self-adjust. You must also be monitored for side effects such as cognitive slowing, kidney stones, metabolic acidosis, heat intolerance, and serious rash.
Other Oral Options
If Zonisamide is not effective or causes side effects, doctors may try other medications, although the evidence for these is based on smaller studies or individual case reports:
- Clonazepam: Often used to help calm the quick jerks, though its effectiveness varies significantly between patients, and it carries significant risks of sedation, dependence, and dangerous interactions with alcohol or opioids [5][6].
- Levetiracetam or Valproate: These are sometimes used for certain types of myoclonus, but they carry risks. Levetiracetam can cause behavioral irritability, and valproate carries serious risks for pregnancy and liver toxicity [7][8].
- Anticholinergics: Occasionally used to help with the dystonia (twisting) component, though they may have side effects in some patients, including cognitive fogginess, dry mouth, and urinary issues [9].
Focal Treatments: Botulinum Toxin
When the dystonia is “focal”—meaning it only affects one or two parts of the body—Botulinum toxin (often known by the brand name Botox) can be an effective tool [2].
- Targeted Relief: These injections are used to temporarily “weaken” the specific muscles that are cramping or twisting.
- Common Targets: Doctors often use these injections for writer’s cramp (hand dystonia) or cervical dystonia (neck twisting) [2][10]. However, injections for speech or swallowing problems require particular expertise because weakness can worsen dysphagia or aspiration.
Treating the Psychiatric Core
A critical part of the standard of care is recognizing that psychiatric symptoms like OCD, anxiety, and depression are commonly associated with MDS and must be addressed [11][12].
- Formal Assessment: Every person with MDS should have regular, formal psychiatric screenings [2]. Waiting for these issues to “go away” on their own is rarely successful.
- Targeted Treatment: Psychiatric symptoms should be treated with the same priority as the movement symptoms [2]. This may involve specialized therapy (like Cognitive Behavioral Therapy with Exposure and Response Prevention for OCD) or individualized psychiatric medications, though research specifically for MDS is still growing [13][14].
Rehabilitation and Support
Medication is only one part of the puzzle. Working with occupational therapists and physical therapists can help you find practical ways to manage daily tasks [2]. For example, they can help with:
- Adaptive tools for eating, drinking, and writing [2][15].
- Gait training if the dystonia affects how you walk [15].
- Speech therapy if myoclonus affects your voice [16][2].
By coordinating all these treatments, you and your care team can focus on improving your quality of life and maintaining your independence [2].
Common questions in this guide
Which medicine has the best evidence for treating MDS?
How is zonisamide started for myoclonus-dystonia syndrome?
Can Botox help the dystonia in MDS?
How are OCD, anxiety, or depression treated in people with MDS?
What therapies besides medicine can help with MDS?
What other medications might doctors try for MDS?
Get notified when new evidence is published on Myoclonus-dystonia syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia.
Hainque E, Vidailhet M, Cozic N, et al.
Neurology 2016; (86(18)):1729-35 doi:10.1212/WNL.0000000000002631.
PMID: 27053715 - 2
Approach to Myoclonus Dystonia Syndrome: A European Reference Network Survey.
Vanegas MI, Marcé-Grau A, Cazurro-Gutiérrez A, et al.
Movement disorders clinical practice 2025; (12(7)):957-968 doi:10.1002/mdc3.70028.
PMID: 40088059 - 3
Medical management of myoclonus-dystonia and implications for underlying pathophysiology.
Fearon C, Peall KJ, Vidailhet M, Fasano A
Parkinsonism & related disorders 2020; (77()):48-56 doi:10.1016/j.parkreldis.2020.06.016.
PMID: 32622300 - 4
[Zonisamide treatment in myoclonus-dystonia].
Salamon A, Zádori D, Horváth E, et al.
Orvosi hetilap 2019; (160(34)):1353-1357 doi:10.1556/650.2019.31472.
PMID: 31423828 - 5
SGCE Myoclonus Dystonia: A Case Report.
Deginet E, Tewoflos M, Abebe YN
Ethiopian journal of health sciences 2025; (35(3)):222-224 doi:10.4314/ejhs.v35i3.11.
PMID: 40717718 - 6
Infantile Epsilon-Sarcoglycan (SGCE) Myoclonus-Dystonia: Diagnostic Pitfalls and Poor Response to Pharmacologic Treatment.
Pissarra R, Dias L, Sousa R, Melo C
Cureus 2025; (17(12)):e100342 doi:10.7759/cureus.100342.
PMID: 41613668 - 7
Myoclonus: Pathophysiology and Treatment Options.
Levy A, Chen R
Current treatment options in neurology 2016; (18(5)):21 doi:10.1007/s11940-016-0404-7.
PMID: 27039330 - 8
Myoclonus-dystonia syndrome: case report.
Akarsu EO, Surmeli R, Yalcin D
Northern clinics of Istanbul 2014; (1(3)):187-190 doi:10.14744/nci.2014.28247.
PMID: 28058330 - 9
Bilateral Pallidal Stimulation in a Family With Myoclonus Dystonia Syndrome Due to a Mutation in the Sarcoglycan Gene.
Sobstyl M, Stapińska-Syniec A, Zaremba J, et al.
Neuromodulation : journal of the International Neuromodulation Society 2022; (25(6)):918-924 doi:10.1111/ner.13362.
PMID: 33497502 - 10
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset.
Todisco M, Gana S, Cosentino G, et al.
Parkinsonism & related disorders 2020; (78()):129-133 doi:10.1016/j.parkreldis.2020.07.026.
PMID: 32823241 - 11
Psychiatric disorders, myoclonus dystonia and SGCE: an international study.
Peall KJ, Dijk JM, Saunders-Pullman R, et al.
Annals of clinical and translational neurology 2016; (3(1)):4-11 doi:10.1002/acn3.263.
PMID: 26783545 - 12
Myoclonus-dystonia: Distinctive motor and non-motor phenotype from other dystonia syndromes.
Timmers ER, Smit M, Kuiper A, et al.
Parkinsonism & related disorders 2019; (69()):85-90 doi:10.1016/j.parkreldis.2019.10.015.
PMID: 31706131 - 13
A mixed-ethnicity myoclonus-dystonia patient with a novel SGCE nonsense mutation: a case report.
de Leon MAJ, Rosales RL, Klein C, Westenberger A
BMC neurology 2022; (22(1)):11 doi:10.1186/s12883-021-02530-z.
PMID: 34986800 - 14
Psychiatric and Behavioral Complications of GPi DBS in an Adolescent with Myoclonus Dystonia.
Kriegel G, Stuckey MI
Case reports in psychiatry 2019; (2019()):1947962 doi:10.1155/2019/1947962.
PMID: 31275687 - 15
Delineating the motor phenotype of SGCE-myoclonus dystonia syndrome.
Vanegas MI, Marcé-Grau A, Martí-Sánchez L, et al.
Parkinsonism & related disorders 2020; (80()):165-174 doi:10.1016/j.parkreldis.2020.09.023.
PMID: 33022436 - 16
Natural history of SGCE-associated myoclonus dystonia in children and adolescents.
De Francesch V, Cazurro-Gutiérrez A, Timmers ER, et al.
Developmental medicine and child neurology 2025; (67(6)):740-749 doi:10.1111/dmcn.16214.
PMID: 39679832
This page is for informational purposes only and does not constitute medical advice. Do not start, stop, or adjust medication or injections without guidance from your movement-disorder neurologist and mental-health care team.